Heptachem & Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 24-06-2024
- Paid Up Capital ₹ 1.25 Cr
as on 24-06-2024
- Company Age 15 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.46 Cr
as on 24-06-2024
- Satisfied Charges ₹ 5.00 Cr
as on 24-06-2024
- Revenue 24.74%
(FY 2023)
- Profit 10.78%
(FY 2023)
- Ebitda 19.61%
(FY 2023)
- Net Worth 21.76%
(FY 2023)
- Total Assets 43.69%
(FY 2023)
About Heptachem & Pharma (India)
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.25 Cr.
The company currently has active open charges totaling ₹9.46 Cr. The company has closed loans amounting to ₹5.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sreepathi Raghavendra and Ashok Nagamalla serve as directors at the Company.
- CIN/LLPIN
U24233TG2009PTC062485
- Company No.
062485
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Heptachem & Pharma (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Nagamalla  | Director | 07-Aug-2020 | Current |
| Sreepathi Raghavendra | Director | 07-Aug-2020 | Current |
Financial Performance of Heptachem & Pharma (India).
Heptachem & Pharma (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 24.74% increase. The company also saw a substantial improvement in profitability, with a 10.78% increase in profit. The company's net worth Soared by an impressive increase of 21.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Heptachem & Pharma (India)?
In 2023, Heptachem & Pharma (India) had a promoter holding of 7.56% and a public holding of 92.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 19 May 2023 | ₹1.50 Cr | Open |
Axis Bank Limited Creation Date: 20 Sep 2022 | ₹3.20 M | Open |
State Bank Of India Creation Date: 07 Feb 2022 | ₹4.28 Cr | Open |
How Many Employees Work at Heptachem & Pharma (India)?
Heptachem & Pharma (India) has a workforce of 56 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Heptachem & Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Heptachem & Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
